RhumbLine Advisers’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

RhumbLine Advisers’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-21,720	Closed	-$57K	–	3187
2020 Q1	$57K	Hold	21,720	–	–	﹤0.01%	2852
2019 Q4	$26K	Hold	21,720	–	–	﹤0.01%	2936
2019 Q3	$37K	Buy	21,720 +1,850	+9%	+$5.63K	﹤0.01%	2938
2019 Q2	$94K	Buy	19,870 +7,812	+65%	+$43.7K	﹤0.01%	2935
2019 Q1	$78K	Buy	+12,058	New	+$63.1K	﹤0.01%	2890

RhumbLine Advisers's NTGN Position: Q2 2020 in Review

RhumbLine Advisers sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 21,720 shares — an estimated $57K sold.

RhumbLine Advisers first reported a position in NTGN in Q1 2019 and held it in 5 quarters. The position peaked at $94K in Q2 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

RhumbLine Advisers reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
RhumbLine Advisers sold 21,720 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $57K.
RhumbLine Advisers first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
RhumbLine Advisers's Neon Therapeutics, Inc. Common Stock position peaked at $94K in Q2 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.